CIK 0001498382 · Non-accelerated filer<br>Smaller reporting company
TuHURA Biosciences, Inc./NV
Sign in to watch- Ticker
- HURA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 990360497
- Phone
- 813-875-6600
- Business address
- 10500 UNIVERSITY CENTER DR., SUITE 110, TAMPA, FL, 33612
- Former names
- Kintara Therapeutics, Inc., DelMar Pharmaceuticals, Inc., Berry Only Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-18 | Ng George K Director | Grant or award · Options (Right to Buy) | +13,553 | 13,553 | ||
| 2024-10-18 | List Alan Director | Grant or award · Options (Right to Buy) | +13,553 | 13,553 | ||
| 2024-10-18 | List Alan Director | Grant or award · Options (Right to Buy) | +13,553 | 13,553 | ||
| 2024-10-18 | MANUSO JAMES S J Director | Grant or award · Options (Right to Buy) | +13,553 | 13,553 | ||
| 2024-10-18 | MANUSO JAMES S J Director | Grant or award · Options (Right to Buy) | +13,553 | 13,553 | ||
| 2024-10-18 | Bianco James A. Chief Executive Officer | Grant or award | +2,323,307 | 2,323,307 | ||
| 2024-10-18 | Bianco James A. Chief Executive Officer | Grant or award · Options (Right to Buy) | +357,800 | 357,800 | ||
| 2024-10-18 | Bianco James A. Chief Executive Officer | Grant or award · Options (Right to Buy) | +71,560 | 71,560 | ||
| 2024-10-18 | Bianco James A. Chief Executive Officer | Grant or award · Options (Right to Buy) | +191,280 | 191,280 | ||
| 2024-10-18 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +33,991 | 33,991 | ||
| 2024-10-18 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +68,438 | 68,438 | ||
| 2024-10-18 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +232,570 | 232,570 | ||
| 2024-10-18 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +15,744 | 15,744 | ||
| 2024-10-18 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +66,658 | 66,658 | ||
| 2023-08-30 | Johnson Laura L. Director | Grant or award · Options (Right to Buy) | +8,500 | 8,500 | ||
| 2023-08-30 | Hoffman Robert E. President, CEO and Interim CFO | Grant or award · Options (Right to Buy) | +23,142 | 23,142 | ||
| 2023-08-30 | TOTH ROBERT JOSEPH JR Director | Grant or award · Options (Right to Buy) | +8,500 | 8,500 | ||
| 2023-08-30 | FAVORITO TAMARA A Director | Grant or award · Options (Right to Buy) | +8,500 | 8,500 | ||
| 2023-08-30 | Brown Dennis M Chief Scientific Officer | Grant or award · Options (Right to Buy) | +10,175 | 10,175 | ||
| 2023-06-01 | Hoffman Robert E. President, CEO, and CFO | Grant or award | +59,800 | 68,902 |
Page 2 of 18 · 357 trades